Stratified prebiotic adjunct therapy guided by baseline fecal SCFA‑producer abundance and host kynurenine pathway genotype improves antidepressant efficacy

Hypothesis

Baseline levels of fecal short‑chain fatty acid (SCFA)‑producing bacteria and host polymorphisms in the kynurenine pathway enzymes (IDO1, TDO2) predict whether a specific prebiotic (e.g., galacto‑oligosaccharides) will augment the clinical effect of SSRIs in major depressive disorder.

Rationale

• Prebiotics increase fecal serotonin and shift the kynurenine‑to‑tryptophan ratio, but trial results show only a nonsignificant trend (SMD: -0.28) [1].
• Heterogeneity in gut microbial composition leads to variable SCFA production; individuals with low baseline SCFA‑producer abundance may not generate sufficient metabolites to influence central tryptophan metabolism [2].
• Host genetic variation in IDO1/TDO2 alters flux through the kynurenine pathway, affecting neuroactive metabolites that modulate mood [3].
• Combining metagenomic profiling of SCFA‑producer taxa with genotyping of kynurenine enzymes creates a predictive biomarker panel that identifies participants likely to benefit from prebiotic‑SSRI synergy.

Prediction

In a randomized, double‑blind, placebo‑controlled trial, participants stratified as 'high predicted responders' (high baseline SCFA‑producer abundance + favorable kynurenine genotype) receiving galacto‑oligosaccharides plus an SSRI will show a significantly greater reduction in MADRS scores than low‑predicted responders receiving the same prebiotic‑SSRI combo or placebo‑SSRI.

Falsifiability

If the interaction between stratification status and treatment does not produce a significant difference in depressive symptom change (p > 0.05) or if the effect size in high‑responders does not exceed that of low‑responders, the hypothesis is falsified.

Proposed Design

• Recruit 240 adults with moderate‑to‑severe MDD, baseline SCFA‑producer abundance quantified via 16S rRNA sequencing, and IDO1/TDO2 genotyping.
• Randomize 1:1 to prebiotic (10 g/day GOS) or maltodextrin placebo, all receiving a standard SSRI.
• Primary outcome: change in MADRS at week 8.
• Secondary outcomes: fecal SCFA concentrations, plasma kynurenine/tryptophan ratio, serotonin levels.
• Analysis: test interaction between stratification group and treatment using mixed‑effects model.

Potential Impact

Confirming that microbiota‑host genotype stratification unlocks prebiotic efficacy would justify targeted microbiome testing before psychotropic prescriptions, address the current evidence gap [4], and guide AI‑driven multi‑omics models for personalized psychobiotic selection [5].